ARTICLE | Clinical News
Androxal enclomiphene regulatory update
May 28, 2012 7:00 AM UTC
Repros modified an SPA for 2 planned Phase III trials with oral Androxal enclomiphene to treat secondary hypogonadism to include additional secondary endpoints specifying the number of men in the stud...